RxDoctor Payments Data

James McBride, MD

Urology · Durango, CONPI 1891057923

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 82.1% of it on its own, with 53 other manufacturers making up the rest. Among urology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$233,605in general payments, 2019–2025

Across 605 payments — averaging $386.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$192K
  • Endo USA, Inc.$24K
  • Endo Pharmaceuticals Inc.$13K
  • Coloplast$840
  • Astellas Pharma US Inc$531
  • AbbVie$400
  • plus $3K from 48 others

What the payments were for

  • Consulting fees$63,29527%
  • Speaking & faculty fees$138,59859%
  • Travel & lodging$18,2508%
  • Food & beverage$13,2246%
  • Education$2380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,605 in reported general payments places this provider in the 95th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$435,505
Medicare patients
285
Services billed
5,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron48$39,000
GemtesaVibegron19$24,272
Testosterone Cypionate293$17,364
TlandoTestosterone Undecanoate12$11,432
Testosterone35$8,692
Tamsulosin Hcl128$1,641
Cabergoline20$1,477
Celecoxib64$1,472
Potassium Citrate ErPotassium Citrate14$1,395
Anastrozole148$914
Solifenacin Succinate17$713
Finasteride49$629
Tadalafil25$523
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$405
Alfuzosin Hcl ErAlfuzosin Hcl13$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$531$39,00048 claims
Sumitomo Pharma America, Inc.Gemtesa$86$24,27219 claims
Antares Pharma, Inc.Tlando$368$11,43212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 urology providers in Colorado.

Other urology in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →